Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in B Cell Mediated Autoimmune Disease
NCT07305116Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QT-019B in autoimmune disease, systemic lupus erythematosus (SLE), nephrotic syndrome and 3 more, sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoint: Dose-Limiting Toxicity at 28 days. Started Dec 2025; status: recruiting.
02
Drugs
QT-019B
03
Conditions
autoimmune diseasesystemic lupus erythematosus (SLE)nephrotic syndromeIgA nephropathy (IgAN)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT07305116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07305116.